Toxicological study of the anti-HBV agent β-L-thymidine

Frontiers in Viral Hepatitis

Volumn , Issue , 2003, Pages 263-270

  Bridges, Edward G ^a   Bryant, Martin L ^a   Placidi, Laurent ^b   Faraj, Abdesslem ^c   Loi, Anna Giulia ^c   Pierra, Claire ^c   Dukhan, David ^c   Gosselin, Gilles ^d   Imbach, Jean Louis ^d   Hernandez, Brenda ^b   Juodawlkis, Amy ^a   Tennant, Bud ^e   Cretton Scott, Erika ^a   Sommadossi, Jean Pierre ^a  

^a Idenix Pharmaceuticals Inc   (United States)

^b University of Alabama at Birmingham   (United States)

^c Idenix   (France)

^d CNRS   (France)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902048722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044450986-4/50073-4     Document Type: Chapter

References (17)

1. Faulds D, Brogden RN Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992, 44(1):94-116.
2. Whittington R, Brogden RN Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992, 44(4):656-683.
3. Wilde MI, Langtry HD Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993, 46(3):515-578.
4. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987, 317(4):192-197. AZT Collaborative Working Group.
5. Sommadossi J-P, Carlisle R Toxicity of 3'-azido-3'-deoxythymidine and 9-(1, 3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrobial Agents and Chemotherapy 1987, 31(3):452-454.
6. Berman E, Duigou-Osterndorf R, Krown SE, Fanucchi MP, Chou J, Hirsch MS, Clarkson BD, Chou TC Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells. Blood 1989, 74(4):1281-1286.
7. Yoshida Y, Yoshida C Reversal of azidothymidine-induced bone marrow suppression by 2', 3'-dideoxythymidine as studied by hemopoietic clonal culture. AIDS Res Hum Retroviruses 1990, 6(7):929-932.
8. Lerza R, Castello G, Mela GS, Arboscello E, Cerruti A, Bogliolo G, Mencoboni M, Ballarino P, Pannacciulli I In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2', 3'-dideoxycytidine combination. Exp Hematol 1997, 25(3):252-255.
9. Dornsife RE, Averett DR In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother 1996, 40(2):514-519.
10. Kurtzberg J, Carter SG Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro. Exp Hematol 1990, 18(10):1094-1096.
11. Weinberg RS, Chusid ED, Galperin Y, Thomson JC, Cheung T, Sacks HS Effect of antiviral drugs and hematopoietic growth factors on in vitro erythropoiesis. Mt Sinai J Med 1998, 65(1):5-13.
12. Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denman SL, Dunkle LM, Kaul S, McLaren C, Skowron G, Kouttab NM, Kennedy T, Weitberg AB, Curt GA 2', 3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993, 167(1):21-29.
13. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C, Lieberman J, Soo W Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993, 118(10):762-769.
14. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, Hartman N, Johns DG, Broder S Long-term toxicity/activity profile of 2', 3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990, 336(8714):526-529.
15. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995, 333(17):1099-1105.
16. Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richarson FC, Lewis W, Cote PJ, Korba BE, Gerin JL Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998, 128(1):179-191.
17. Richardson FC, Engelhardt JA, Bowsher RR Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci USA 1994, 91(25).